Alemtuzumab in relapsed immune severe aplastic anemia: Long‐term results of a phase II study
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26924
Abstract: Immune severe aplastic anemia (SAA) is characterized by pancytopenia and immune‐mediated bone marrow destruction. SAA may be treated with hematopoietic stem cell transplantation (HSCT) or immunosuppressive therapy (IST). However, 30% of patients treated with IST… read more here.
Keywords: long term; term results; severe aplastic; immune severe ... See more keywords